Edgewise Therapeutics, Inc. (NASDAQ:EWTX) General Counsel Sells $36,987.96 in Stock

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) General Counsel John R. Moore sold 1,956 shares of the firm’s stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $18.91, for a total transaction of $36,987.96. Following the transaction, the general counsel now directly owns 3,252 shares of the company’s stock, valued at approximately $61,495.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

John R. Moore also recently made the following trade(s):

• On Friday, February 9th, John R. Moore sold 8,029 shares of Edgewise Therapeutics stock. The stock was sold at an average price of $20.01, for a total value of $160,660.29.
• On Wednesday, February 7th, John R. Moore sold 17,993 shares of Edgewise Therapeutics stock. The shares were sold at an average price of $20.00, for a total value of $359,860.00.

Edgewise Therapeutics Stock Up 1.2 %

EWTX opened at $19.52 on Monday. The firm’s fifty day simple moving average is $16.90 and its two-hundred day simple moving average is $12.80. Edgewise Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $20.90. The company has a market cap of $1.82 billion, a price-to-earnings ratio of -12.35 and a beta of 0.15.

Edgewise Therapeutics (NASDAQ:EWTX) last issued its quarterly earnings results on Thursday, February 22nd. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). On average, research analysts forecast that Edgewise Therapeutics, Inc. will post -1.76 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on EWTX shares. Truist Financial reaffirmed a “buy” rating and set a $25.00 target price on shares of Edgewise Therapeutics in a report on Wednesday, April 17th. Piper Sandler began coverage on shares of Edgewise Therapeutics in a research report on Thursday, March 7th. They issued an “overweight” rating and a $48.00 price objective for the company. Royal Bank of Canada raised their target price on Edgewise Therapeutics from $28.00 to $32.00 and gave the company an “outperform” rating in a research report on Monday, April 22nd. Finally, Wedbush reaffirmed an “outperform” rating and issued a $26.00 price target on shares of Edgewise Therapeutics in a report on Tuesday, April 16th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Edgewise Therapeutics currently has an average rating of “Buy” and an average target price of $31.20.

Hedge Funds Weigh In On Edgewise Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in EWTX. Quantum Private Wealth LLC increased its position in shares of Edgewise Therapeutics by 2.4% during the fourth quarter. Quantum Private Wealth LLC now owns 63,219 shares of the company’s stock worth $692,000 after purchasing an additional 1,500 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in Edgewise Therapeutics by 3.5% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 116,900 shares of the company’s stock worth $670,000 after purchasing an additional 3,900 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Edgewise Therapeutics by 29.8% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,833 shares of the company’s stock worth $228,000 after buying an additional 4,785 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Edgewise Therapeutics by 349.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,338 shares of the company’s stock valued at $80,000 after buying an additional 5,704 shares during the last quarter. Finally, AJOVista LLC purchased a new position in shares of Edgewise Therapeutics in the fourth quarter worth about $84,000.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.